tion, yet costs half as much. This is because the stream of costs associated with each case of schizophrenia is six times the stream of costs associated with myocardial infarction. To illustrate the utility of this costing approach, the information was used to estimate the cost-benefit ratio likely to follow the introduction of social intervention strategies. The information also showed that Australian support for research in schizophrenia is inadequate when compared with that for myocardial infarction and quite out of proportion to the cost of schizophrenia to the community. ( Schizophrenia affects some 0.5% of the population and produces a large morbidity and a small but definite mor¬ tality. In these ways it is unlike heart disease or cancer, the diseases most commonly costed, for they affect a much larger portion of the community and often produce death rather than chronic disability. In this report we The estimates for the total direct costs are also shown in Table 4 . (Table 5) .
The direct, indirect, and total costs of the prodrome, calculated with the conventions specified previously, are shown in Table 6 Table 4 were $6.58 million, and from a 5% reduction in forgone earnings shown in Table 5 
